Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial

IMPORTANCE: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and first cardiovascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, but patients remain at high risk of recurrent cardiovascular ev...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Cardiol
Main Authors: Murphy, Sabina A., Pedersen, Terje R., Gaciong, Zbigniew A., Ceska, Richard, Ezhov, Marat V., Connolly, Derek L., Jukema, J. Wouter, Toth, Kalman, Tikkanen, Matti J., Im, Kyungah, Wiviott, Stephen D., Kurtz, Christopher E., Honarpour, Narimon, Giugliano, Robert P., Keech, Anthony C., Sever, Peter S., Sabatine, Marc S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6537798/
https://ncbi.nlm.nih.gov/pubmed/31116355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2019.0886
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados